trending Market Intelligence /marketintelligence/en/news-insights/trending/mghf-5lwyipbssrvaok3ow2 content esgSubNav
In This List

Bayer posts YOY rise in Q2 earnings, lowers FY outlook on Monsanto takeover

Video

S&P Capital IQ Pro | Powering Your Edge

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Bayer posts YOY rise in Q2 earnings, lowers FY outlook on Monsanto takeover

Bayer AG said second-quarter earnings rose and lowered its outlook for 2018 to reflect the acquisition of the world's top seed maker, Monsanto Co.

The German agrochemical and pharmaceutical company reported second-quarter core net income from continuing operations of €1.41 billion, or €1.54 per share, up from €1.35 billion, or €1.52 per share, a year earlier.

The S&P Global Market Intelligence consensus normalized EPS estimate for the second quarter was €1.55.

During the quarter, net income from both continuing and discontinued operations amounted to €799 million, down from €1.22 billion in the year-ago period.

Net sales for the second quarter totaled €9.48 billion, up 8.8% on a yearly basis from €8.71 billion.

The company booked research and development expenses of €1.26 billion, an increase from €1.10 billion in the second quarter of 2017.

Bayer's pharmaceuticals segment raked in total net sales of €4.23 billion during the second quarter, down from €4.32 billion a year earlier. The consumer health division also saw a year-over-year decline in sales to €1.41 billion from €1.55 billion.

Meanwhile, the crop science division's second-quarter total net sales rose year over year to €3.02 billion from €2.17 billion. The animal health business recorded sales of €456 million, up from €451 million in the second quarter of 2017.

For the second half, Bayer reported core net income from continuing operations of €3.39 billion, up from €3.36 billion a year earlier. Core EPS from continuing operations declined year over year to €3.77 from €3.80.

Bayer revised its outlook for full year 2018 to take into account the Monsanto acquisition, which closed June 7. The company now anticipates core EPS to decline by a high-single-digit percentage, or between €5.70 and €5.90. Previously, the company said it expects core EPS to be steady to year-ago levels.

The S&P Global Market Intelligence consensus normalized EPS estimate for 2018 is €6.08.

Bayer, whose newly acquired Monsanto unit is facing thousands of lawsuits related to its top-selling herbicide, said it expects sales of more than €39 billion in 2018, with more than €5 billion attributable to the acquired business. Previously, the company said it expects full-year sales of below €35 billion.